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Background: Both of UFT-/Tegafur-based postoperative chemotherapy 
and postoperative radiotherapy have made large progress in treatment of 
early-stage non-small cell lung cancer. While it is unclear that, whether 
UFT-/Tegafur-based postoperative chemotherapy is superior to postopera-
tive radiotherapy for early-stage non-small cell lung cancer with no direct 
evidence. Methods: Electronic databases (Pubmed, embase, cochrane 
library and clinicaltrials.gov) were searched to obtain relevant studies. 
This systematic review and meta-analysis is reported in accordance with 
the Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) 
Statement and was registered at International Prospective Register of 
Systematic Reviews (number CRD42018095979). Sensitive analysis was 
conducted by excluding overweight studies. Funnel plot and egger’s test 
were performed to conduct publication bias. Results: Twenty-one random-
ized control trials were included. Our results suggested UFT-/Tegafur-based 
postoperative chemotherapy could improve overall survival over postoper-
ative radiotherapy [HR=0.69 (0.59-0.80), p=0.000]. But subgroup analysis 
about stage showed there was no significant difference between them, no 
matter of stage I, II and III. As to chemotherapy regime, both UFT-/Tegafur 
+ platinum+vinca alkaloid [HR=0.68 (0.56-0.82), p=0.000] and UFT-/Tega-
fur only [HR=0.66 (0.54-0.79), p=0.000] were superior to radiotherapy. 
Subgroup analysis about radiotherapy delivery method and dose showed, 
significant improvement of chemotherapy over radiotherapy for Cobalt-60 
only [HR=0.54 (0.39-0.75), p=0.000], Cobalt-60 and linac [HR=0.69 (0.59-
0.81), p=0.000] and ≥45 Gy [HR=0.64 (0.54-0.75), p=0.000], but not for 
linac only [HR=0.78 (0.60-1.03), p=0.081] and ≥ 45 Gy [HR=0.86 (0.67-
1.11), p=0.241]. Conclusion: UFT-/Tegafur-based postoperative chemo-
therapy was superior to postoperative radiotherapy for improving overall 
survival of early-stage non-small cell lung cancer, but it is not always so 
under certain circumstance, such as RT delivery method and radiation dose. 
Of course, it is imperative to further explore differences in specific stage, 
such as I A and I B. 
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1. Introduction
Non-small cell lung cancer (NSCLC) is a malig-nant tumor with high mortality, accounting for about 85% of lung cancer. [1] Because of the high 
invasiveness and rapid progress, it is very important to 
carry out effective treatment of NSCLC in the early stage. 
Although surgical resection is currently the standard 
treatment for early NSCLC, long-term postoperative sur-
vival is unsatisfactory. [2-3] Therefore, many studies have 
explored the efficacy of postoperative UFT/Tegafur-based 
adjuvant chemotherapy and radiotherapy.
Through systematic retrieval, we have found that most 
studies have shown that UFT/Tegafur based adjuvant 
chemotherapy improves overall survival, [4-6] but postop-
erative radiotherapy seems not. [7-8] In addition, most cli-
nicians also think that postoperative UFT/Tegafur-based 
adjuvant chemotherapy is better than postoperative radio-
therapy, but there is no direct evidence. Moreover, new 
studies have found that postoperative radiotherapy may 
also improve survival rates in early non-small cell lung 
cancer patients. [9-10] Therefore, the difference of UFT/
Tegafur-based postoperative adjuvant chemotherapy and 
postoperative radiotherapy in the treatment of early non-
small cell lung cancer is puzzling. In recent years, net-
work meta-analysis, a method of obtaining evidence from 
evidence-based medicine, has been paid much attention 
to. Indirect comparison, as a special type of meta-analysis 
with reliabie results, [11-12] is also widely used. [13-14] Giv-
en no report of direct comparison between UFT/Tegafur 
based postoperative adjuvant chemotherapy and radio-
therapy in treatment of early-stage non-small cell lung 
cancer, we performed this systematic review and network 
meta-analysis, expecting to provide assistance for clinic.
2. Methods
2.1 Search Strategy
Relevant published or unpublished RCT studies were se-
lected by searching Pubmed, Embase, Cochrane library and 
ClinicalTrials.gov. We used MESH terms “chemotherapy”, 
“radiotherapy”, “surgery” and “Carcinoma, non-small cell 
lung”, and the retrieval strategy of Pubmed as follow: sur-
gery[Title/Abstract] OR “General Surgery” [Mesh] AND 
Therapy, Drug [Title/Abstract] OR Drug Therapies [Title/
Abstract] OR Therapies, Drug [Title/Abstract] OR Chemo-
therapy [Title/Abstract] OR Chemotherapies Pharmacother-
apy [Title/Abstract] OR Pharmacotherapies [Title/Abstract] 
OR “Drug Therapy” [Mesh] AND  placebo [Title/Abstract] 
OR “Controlled Clinical Trial” [Publication Type] OR 
“Randomized Controlled Trial” [Publication Type] AND 
Carcinoma, Non Small Cell Lung [Title/Abstract] OR Car-
cinomas, Non-Small-Cell Lung [Title/Abstract] OR Lung 
Carcinoma, Non-Small-Cell [Title/Abstract] OR Lung Car-
cinomas, Non-Small-Cell [Title/Abstract] OR Non-Small-
Cell Lung Carcinomas [Title/Abstract] OR Nonsmall Cell 
Lung Cancer [Title/Abstract] OR Non-Small-Cell Lung 
Carcinoma [Title/Abstract] OR Non Small Cell Lung Car-
cinoma [Title/Abstract] OR Carcinoma, Non-Small Cell 
Lung [Title/Abstract] OR Non-Small Cell Lung Cancer 
[Title/Abstract] OR “Carcinoma, Non-Small-Cell Lung” 
[Mesh] OR  radiation therap* [Title/Abstract] OR PORT 
[Title/Abstract] OR Radiother* [Title/Abstract] OR “Radio-
therapy” [Mesh] AND surgery [Title/Abstract] OR “General 
Surgery” [Mesh] AND Carcinoma, Non Small Cell Lung 
[Title/Abstract] OR Carcinomas, Non-Small-Cell Lung [Ti-
tle/Abstract] OR Lung Carcinoma, Non-Small-Cell [Title/
Abstract] OR Lung Carcinomas, Non-Small-Cell [Title/
Abstract] OR Non-Small-Cell Lung Carcinomas [Title/Ab-
stract] OR Nonsmall Cell Lung Cancer [Title/Abstract] OR 
Non-Small-Cell Lung Carcinoma [Title/Abstract] OR Non 
Small Cell Lung Carcinoma [Title/Abstract] OR Carcino-
ma, Non-Small Cell Lung [Title/Abstract] OR Non-Small 
Cell Lung Cancer [Title/Abstract] OR “Carcinoma, Non-
Small-Cell Lung” [Mesh] AND placebo [Title/Abstract]) 
OR “Controlled Clinical Trial” [Publication Type] OR 
“Randomized Controlled Trial” [Publication Type]. Addi-
tional new studies were identified by reading included stud-
ies and relevant reviews. All of the postoperative chemo-
therapy regime was UTF/Tegarfur-based. This systematic 
review and meta-analysis is reported in accordance with the 
Preferred Items for Systematic Reviews and Meta-analysis 
(PRISMA) Statement and was registered at Internation-
al Prospective Register of Systematic Reviews (number 
CRD42018095979). Randomized control trials were in-
cluded if they met following criteria: (1) postoperative che-
motherapy vs surgery alone; (2) postoperative radiotherapy 
vs surgery alone; (3) early-stage non-small cell lung cancer; 
(4) providing estimates of overall survival. 
2.2 Data Extraction
Two authors (LX Yu and M Song) independently extract-
ed the original data. Disagreement was resolved by dis-
cussion. The extracted data were consisted of the follow 
items: the first author’s name, publication year, methods, 
study design, matching criteria, total number of cases and 
controls, stage and therapy regime.
2.3 Statistical Analysis
Review manager 5.3 and Stata 14.0 were performed to 
conduct this meta-analysis. Taking low heterogeneity into 
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account, we use fixed effect model to pool estimates. In ad-
dition, we excluded the researches with overweight to con-
duct sensitive analysis and implement subgroup analysis to 
explore the differences of postoperative chemotherapy and 
postoperative radiotherapy of non-small cell lung stage and 
therapy regime. Publication bias was tested by funnel plot 
and egger’s test, and P value of egger’s test ＜ 0.05 is con-
sidered significant. Hazard ratio with 95%CI and odds ratio 
with 95%CI were used to assess estimates of survival.  
3. Results
3.1 Eligible Studies
As shown in Figure 1, total twenty-one randomized 
control trials [15-35] were identified finally, eleven about 
postoperative UFT/Tegafur-based chemotherapy [15-25] 
and ten about postoperative radiotherapy. [26-35] Two stud-
ies were from Study Group for Adjuvant Chemotherapy 
for Lung Cancer (SGACLC ACTLC), and one study was 
from Lung Cancer Study Group (LCSG). Especially, one 
study obtained from the reference is an unpublished data. 
Characteristics of included studies were shown in Table 
1. The range of size was from 58 to 999, and chemother-
apy regime mainly contained UFT/Tegarfur + platinum 
+ vinca alkaloid and UFT/Tegarfur only. Characteristics 
of included studies were shown in Table 1. Methodolog-
ical quality graph and summary were in Figure 2 and 
Figure 3.
Table 1. Characteristics of included studies
Study, year Methods Size (n) Intervention Stage Therapy regime
SGACLC ACTLC, 1992 RCT:1982 to 1985 306 Postoperative CT NK Cisplatin,mitomycin,tegafur
SGACLC ACTLC, 1995 RCT:1985 to 1987 332 Postoperative CT Ⅰ ,Ⅱ ,Ⅲ Cisplatin,doxorubicin,UFT
Wada H, 1996
RCT:1985 to 1988 208 Postoperative CT Ⅰ ,Ⅱ ,Ⅲ Tegarfur,uracil
RCT:1985 to 1988 323 Postoperative CT Ⅰ ,Ⅱ ,Ⅲ Cisplatin,vindesine,UFT
Wada H, 1999 RCT:1988 to 1989 225 Postoperative CT Ⅰ ,Ⅱ Cisplatin,vindesine,mitomy-cin,tegarfur,uracil
Xu G, 1998 RCT:1989 to 1992 70 Postoperative CT Ⅰ ,Ⅱ ,Ⅲ Cisplatin,vindesine,doxorubicin,cy-clophosphamide
Imaizumi M, 2005
RCT:1982 to 1988 104 Postoperative CT Ⅰ Cisplatin,vindesine,tegarfur,uracil
RCT:1992 to 1995 104 Postoperative CT Ⅰ Tegarfur,uracil
Nakagawa M, 2005 RCT:1991 to 1994 367 Postoperative CT Ⅰ ,Ⅱ Tegarfur,uracil
Nakagawa K, 2006
RCT:1992 to 1994 172 Postoperative CT Ⅰ Tegarfur,uracil
RCT:1992 to 1994 95 Postoperative CT Ⅱ ,Ⅲ Cisplatin,vindesine,tegarfur,uracil
Sawamura K, 1988
RCT:1982 to 1987 321 Postoperative CT Ⅰ Tegarfur
RCT:1982 to 1986 83 Postoperative CT Ⅱ ,Ⅲ Doxorubicin,mitomycin,tegarfur
RCT:1982 to 1987 28 Postoperative CT Ⅱ Cisplatin,tegarfur
Endo C, 2003 RCT:1992 to 1994 219 Postoperative CT Ⅰ ,Ⅱ Tegarfur,uracil
Kato H, 2004 RCT:1994 to 1997 999 Postoperative CT Ⅰ Tegarfur,uracil
Chang Y,2015 Pooled analysis of RCT 58 Postoperative RT Ⅰ
54 Gy in three 18 Gy fractions/ 50 
Gy in four 12.5 Gy fractions within 
5 days
54 Gy in three 18 Gy fractions 
over 5-8 days/ 60 Gy in four 12 Gy 
fractions over 10-14 days
Park JH, 2007 RCT:1989 to 1998 111 Postoperative RT Ⅱ ,Ⅲ 50.4 to 55.8 Gy in 1.8 to 2 Gy fractions, 5 times a week
EORTC 0886, 2000 RCT:1986 to 1990 106 Postoperative RT Ⅱ ,Ⅲ 56 Gy in 28 fractions in 5.5 weeks
van Houtte P, 1980 RCT:1966 to 1977 224 Postoperative RT Ⅰ ,Ⅱ ,Ⅲ 60 Gy in 30 fractions in 6 weeks
Feng QF, 2000 RCT:1981 to 1995 317 Postoperative RT Ⅱ ,Ⅲ 60 Gy in 30 fractions in 6 weeks
Dautzenberg B, 1999
RCT:1986 to 1994 189 Postoperative RT Ⅰ ,Ⅱ ,Ⅲ 60 Gy in 24 to 30 fractions in 6 weeks
RCT:1988 to 1994 539 Postoperative RT Ⅰ ,Ⅱ ,Ⅲ 60 Gy in 24 to 30 fractions in 6 weeks
LCSG, 1986 RCT:1978 to 1985 230 Postoperative RT Ⅱ ,Ⅲ 50 Gy in 25 to 27.5 fractions in 5 to 5.5 weeks
Stephens RJ, 1996 RCT:1986 to 1993 308 Postoperative RT Ⅱ ,Ⅲ 40 Gy in 15 fractions in 3 weeks
Lafitle JJ, 1996 RCT:1985 to 1991 163 Postoperative RT Ⅰ 45 to 60 Gy in 22.5 to 30 fractions in 6weeks
Trodella L, 2002 RCT:1989 to 1997 104 Postoperative RT Ⅰ 50.4 Gy in 1.8 Gy/d in 5 weeks and 3 days
NK, not known; RCT, randomised controlled trial; CT, chemotherapy; RT, radiotherapy; Gy-Gray,unit of radiotherapy dose; UFT, Uracil/
tegafur
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Figure 1. Quality of reporting of meta-analyses flow dia-
gram.
Figure 2. Methodological quality graph: review authors’ 
judgements about each methodological quality item pre-
sented as percentages across all included studies
Figure 3. Methodological quality summary: review au-
thors’ judgements about each methodological quality item 
for each included study
Figure 4. Forest plots of postoperative chemotherapy vs surgery alone group (A) and postoperative radiotherapy vs 
surgery alone group (B)
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3.2 Overall Survival
For overall survival, the pooled Hazard Ratios of death 
were 0.80 (0.71-0.90, p=0.0002) and 1.16 (1.06-1.27, 
p=0.003) in postoperative UFT/Tegarfur-based chemo-
therapy vs surgery alone group and postoperative radio-
therapy vs surgery alone group, respectively. Network 
indirect comparison suggested that postoperative UFT/
Tegarfur-based chemotherapy could improve overall sur-
vival over postoperative radiotherapy [HR=0.69 (0.59-
0.80), p=0.000], which was shown in Table 2.
3.3 Subgroup Analysis
To explore potential influential factors, subgroups analysis 
about non-small cell lung cancer stage and therapy regime 
were performed. For stage, there no evidence of important 
statistical significance between postoperative chemother-
apy and postoperative radiotherapy [stage Ⅰ HR=0.80 
(0.64-1.00), p=0.051, stage Ⅱ HR=0.79 (0.50-1.26), 
p=0.324, stage Ⅲ HR=0.88 (0.58-1.36), p=0.574]. For 
chemotherapy regime, both UFT/Tegarfur+platinum+vin-
ca alkaloid and UFT/Tegarfur only could improve over-
all survival over radiotherapy [HR=0.68 (0.56-0.82), 
p=0.000, 0.66 (0.54-0.79), p=0.000]. In terms of RT de-
livery method, postoperative chemotherapy is superior to 
postoperative radiotherapy in Cobalt-60 only [HR=0.54 
(0.39-0.75), p=0.000] and Cobalt-60 and linac [HR=0.69 
(0.59-0.81), p=0.000], but not in linac only[HR=0.78 
(0.60-1.03), p=0.081]. Similarly, with ≥45 Gy radiation 
dose, there existed significant difference between post-
operative chemotherapy and postoperative radiotherapy 
[OR=0.64 (0.54-0.75), p=0.000], while not with ＜ 45 Gy 
radiation dose [OR=0.86 (0.67-1.11), p=0.241]. The main 
results were shown in Table 2.
Table 2. Summary effect of survival index
Outcome/Sub-
group
No. Of 
patients
Statistical method Effect size(relative 
value)
P value
Overall surviv-
al 3956/2349
Hazard Ratio 
(Fixed, 95%CI)
0.69 (0.59-
0.80) 0.000
Subgroup
(stage)
Stage I 2574/572 Hazard Ratio (Fixed, 95%CI)
0.80 (0.64-
1.00) 0.051
Stage II 190/817 Hazard Ratio (Fixed, 95%CI)
0.79 (0.50-
1.26) 0.324
Stage III 178/746 Hazard Ratio (Fixed, 95%CI)
0.88 (0.58-
1.36) 0.574
Subgroup
(chemothera-
py regime)
UFT/Tega-
fur+P+VA 1375/2349
Hazard Ratio 
(Fixed, 95%CI)
0.68 (0.56-
0.82) 0.000
UFT/Tegafur 
only 2390/2349
Hazard Ratio 
(Fixed, 95%CI)
0.66 (0.54-
0.79) 0.000
Subgroup
(RT delivery 
method)
Cobalt-60 only 3956/202 Hazard Ratio (Fixed, 95%CI)
0.54 (0.39-
0.75) 0.000
Cobalt-60 and 
linac 3956/2063
Hazard Ratio 
(Fixed, 95%CI)
0.69 (0.59-
0.81) 0.000
Linac only 3956/395 Hazard Ratio (Fixed, 95%CI)
0.78 (0.60-
1.03) 0.081
Subgroup
(radiation 
dose)
≥45 Gy 3956/2019 Odds Ratio (Fixed, 95%CI)
0.64 (0.54-
0.75) 0.000
＜ 45 Gy 3956/382 Odds Ratio (Fixed, 95%CI)
0.86 (0.67-
1.11) 0.241
No. Of patients, postoperative chemotherapy/postoperative radio-
therapy
P+VA, platinum+vinca alkaloid
3.4 Sensitive Analysis and Publication Bias
We excluded overweight studies, such as Kato et al, SGA-
CLC ACTLC and Dautzenberg2 et al, to conduct sensitive 
analysis, and final result was not changed [HR=0.69 (0.57-
0.84), p=0.000]. Funnel plots were shown in Figure 4. 
Egger’s test suggested that there was no publication bias 
in postoperative UFT/Tegarfur-based chemotherapy group 
(p=0.637) and postoperative radiotherapy group (p=0.417).
Figure 5. Funnel plots of postoperative chemotherapy vs 
surgery alone group (A) and postoperative radiotherapy vs 
surgery alone group (B)
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4. Discussion
Surgical resection is the recommended method for the 
treatment of non-small cell lung cancer, but the postop-
erative survival rate is always unsatisfactory, even in the 
early stage, the 5-year survival rate is only 45.1%, [36] so 
the choice of postoperative adjuvant treatment is very 
important. Recent years, many scholars have studied the 
effects of postoperative UFT/Tegarfur-based adjuvant che-
motherapy and adjuvant radiotherapy in the treatment of 
early-stage non-small cell lung cancer. The results showed 
that UFT/Tegarfur-based adjuvant chemotherapy seemed 
to be superior to postoperative adjuvant radiotherapy, but 
there was no definitive comparative evidence. Therefore, 
we wonder much that UFT / Tegarfur based adjuvant 
chemotherapy is really better than postoperative adjuvant 
radiotherapy? If so, is it true for every aspect, such as 
specific stage? Based on that, we conducted the network 
meta-analysis. Our results showed that UFT/Tegarfur 
based adjuvant chemotherapy could significantly improve 
the overall survival rate of patients [HR=0.69 (0.59-0.80) 
p=0.000] compared with postoperative adjuvant radiother-
apy, but it also changed with different stages and radio-
therapy methods.
UFT is an oral fluorouracil preparation that combines 
tegafur, a prodrug of 5-fluorouracil, with uracil, which 
inhibits dihydropyrimidine dehydrogenase, the rate-lim-
iting enzyme responsible for 5-fluorouracil catabolism. 
Tegafur, the major component of UFT, is metabolized to 
gamma-hydroxybutyric acid and gammabutyrolactone, 
which inhibit angiogenesis. In recent years, UFT/Tegar-
fur-based postoperative adjuvant chemotherapy has made 
great progress in the treatment of early non-small cell lung 
cancer. Hotta K et al [4] discovered that therapy with tega-
fur and uracil (UFT; HR, 0.799; 95% CI, 0.668 to 0.957; 
P =0.015) could yield a significant survival benefit to 
early-stage NSCLC. In 2005, Hamada C et al [37] showed 
that postoperative adjuvant chemotherapy with UFT was 
associated with improved 5- and 7-year survival in a Jap-
anese early-stage NSCLC patient population, whose over-
all pooled hazard ratio was 0.74 and 95% CI was 0.61 to 
0.88 (P =0.001). And in 2009, Hamada C et al [6] reported 
significant hazard ratio even was 0.62, with much better 
than before. UFT/Tegarfur based postoperative adjuvant 
chemotherapy may be promising for early-stage NSCLC.
Most previous studies [7-8] have shown that postopera-
tive radiotherapy couldn’t effectively improve the survival 
rate of early non-small cell lung cancer patients, so the 
clinical treatment of this program is relatively conserva-
tive. But the latest researches have come to the opposite 
conclusions. Sakib N et al [9] suggested that the addition 
of PORT significantly improves survival in patients with 
resectable stage IIIA-N2 NSCLC [HR=0.73（0.58-0.92）,P 
= 0.008]. Likewise, Patel SH et al [10] reached similar con-
clusion in III-N2 NSCLC [HR=0.73（0.58-0.92）,P = 
0.008]. In the face of this outcome, we included random-
ized controlled trials of higher quality, and the results sug-
gested that postoperative radiotherapy might not improve 
the survival rate of patients with early non-small cell lung 
cancer [HR = 1.16 (1.06-1.27), P = 0.003]. But this does 
not necessarily mean that UFT/Tegarfur-based postoper-
ative adjuvant chemotherapy is superior to postoperative 
radiotherapy in all aspects.
We therefore further compared the effects of UFT/
Tegarfur-based postoperative adjuvant chemotherapy with 
postoperative radiotherapy, and performed a comprehen-
sive analysis of the different stages, chemotherapy regi-
mens, radiotherapy methods and doses of the subgroups 
Our results suggest that UFT/Tegarfur-based postoper-
ative adjuvant chemotherapy does improve survival in 
patients with early-stage non-small cell lung cancer [HR 
= 0.69 (0.59-0.80), P = 0.000], regardless of the chemo-
therapy regimen（Table 2）. [UFT/Tegafur+P+VA, HR= 
0.68 (0.56-0.82), p=0.000; UFT/Tegafur only, HR= 0.66 
(0.54-0.79), p=0.000]. However, no significant difference 
exhibited in stage. [Stage Ⅰ , HR= 0.80 (0.64-1.00), 
p=0.051; Stage Ⅱ , HR= 0.79 (0.50-1.26), p=0.324；
Stage Ⅲ , HR= 0.88 (0.58-1.36), p=0.574] （Table 2）. 
We may also need sufficient data to further refine staging 
studies, such as I A, I B, II A, III A. In terms of radiother-
apy methods and doses, the results are inconsistent. In the 
cobalt-60, Cobalt-60 ﹢ linac and≥45Gy, the UFT/Tegar-
fur based postoperative adjuvant chemotherapy could im-
prove early-stage NSCLC overall survival over postoper-
ative radiotherapy [Cobalt-60 only, HR=0.54 (0.39-0.75), 
p= 0.000; Cobalt-60 and linac, HR= 0.69 (0.59-0.81), p= 
0.000; ≥45 Gy, HR= 0.64 (0.54-0.75), p= 0.000]（Table 2）, 
However, when Linac only and < 45 Gy, there was no 
significant difference between the two adjuvant regimens. 
[Linac only, HR= 0.78 (0.60-1.03), p= 0.081; ＜ 45 Gy, 
HR= 0.86 (0.67-1.11), p= 0.241].（Table 2）.Therefore, 
UFT/Tegarfur-based postoperative adjuvant chemotherapy 
isn’t always superior to radiotherapy, and the reasons need 
to be further explored. Sensitivity analysis and publication 
bias test showed that our results were stable and reliable.
We also need to point out the limitations of our re-
search. First, we do not have enough data for more de-
tailed phased studies, which may be an important reason 
for the differences in outcomes. Secondly, whether there 
are differences in the effectiveness of histology is the 
question we will explore in the future. Finally, we failed 
to match sample size completely.
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5. Conclusion
Our study suggests that UFT/Tegarfur based postoperative 
adjuvant chemotherapy may not always be superior to post-
operative radiotherapy, and it seems to be closely related 
to specific treatment methods, especially different radio-
therapy interventions. Of course, detailed stage needs to 
be explored in the future. Our results change our previous 
understanding that postoperative UFT/Tegarfur-based che-
motherapy is always superior to postoperative radiotherapy, 
which allows us to weigh the options of different methods.
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